Premium
Bacterial surface display of endoglin by antigen 43 induces antitumor effectiveness via bypassing immunotolerance and inhibition of angiogenesis
Author(s) -
Huang FengYing,
Li Ling,
Liu Quan,
Li YueNan,
Bai RuiZhen,
Huang YongHao,
Zhao HuanGe,
Guo JunLi,
Zhou SongLin,
Wang Hua,
Lin YingYing,
Tan GuangHong
Publication year - 2013
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.28511
Subject(s) - angiogenesis , fusion protein , biology , epitope , recombinant dna , plasmid , chimeric gene , antigen , escherichia coli , immune system , gene , microbiology and biotechnology , cancer research , immunology , genetics , gene expression
Various angiogenesis‐related self‐molecules have been considered to be therapeutic targets. However, the direct use of self‐molecules as vaccines is not recommended because of the inherent ability of the host to develop immune tolerance. Antigen 43 (Ag43) is a surface protein found in E. coli and contains an α and a β subunits, which contains multiple T epitopes in α subunit. Here we construct a novel Ag43 surface display system (Ag43 system) to express Ag43 chimeric proteins to disrupt immune tolerance against self‐molecules. The Ag43 system was constructed from an Escherichia coli strain Tan109, derived from JM109, in which the Ag43 gene was deleted and a recombinant plasmid (pETAg43′) expressing a partial Ag43 gene was introduced. The extracellular domain of angiogenesis‐related endoglin gene was then subcloned into plasmid pETAg43′, resulting in a recombinant plasmid pETAg43′/END e which was then used to transform Tan109 for protein expression. We found that Ag43 and endoglin chimeric protein (Ag43′/END e ) was expressed on the bacterial surface. The chimeric protein could be separated from the bacterial surface by heating to 60°C and yet retain activity. We used Ag43′/END e as a protein vaccine and found that it could disrupt immune tolerance against endoglin by inducing significant antitumor activities and inhibit angiogenesis in several tumor models without significant side effects. These data suggest that Ag43′/END e chimeric protein is a potential model vaccine for active tumor immunotherapy, and that Ag43 system could be an effective tool for novel vaccine preparation to break immune tolerance to other angiogenesis‐related self‐molecules for cancer therapy.